Dorzopt, eye drops 2% 5 ml 3 pcs

Elevated intraocular pressure, Glaucoma

Open-angle (including secondary) glaucoma;

Pseudoexfoliative glaucoma;

Ophthalmohypertension.

Indications

Open-angle (including secondary) glaucoma;

pseudoexfoliative glaucoma;

ophthalmohypertension.

Pharmacological effect

carbonic anhydrase inhibitors

Special instructions

The preservative contained in dorzolamide drops (benzalkonium chloride) can be absorbed by soft contact lenses, causing eye irritation and toxicity. The drug is used only after removing contact lenses.

Contact lenses should be put on no earlier than 15 minutes after instillation. It is necessary to control the content of K+, electrolytes in the blood serum and its pH.
In old age, sensitivity to dorzolamide may increase (dose reduction required).

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Dorzolamide

Composition

Composition: per 1.0 ml of drug:

Active substance:

dorzolamide hydrochloride in terms of dorzolamide 20.00 mg;

Excipients:

hyethylose,

mannitol,

citric acid monohydrate,

sodium hydroxide,

benzalkonium chloride,

purified water.

Description:

clear, colorless solution.

Contraindications

Hypersensitivity to any component, chronic renal failure (creatinine clearance less than 30 ml/min), hyperchloremic acidosis, children under 18 years of age, pregnancy, lactation, oral administration of carbonic anhydrase inhibitors.

Side Effects

Local: burning, paresthesia, itching in the eyes, lacrimation, blurred vision, irritation and swelling of the eyelids, conjunctivitis, superficial punctate keratitis, blepharitis, photophobia;

rarely – iridocyclitis, increased corneal thickness, allergic reactions; hypotony of the eye, retinal detachment in patients after antiglaucomatous operations.

Systemic: bitterness in the mouth, nausea, headache, asthenia, nephrourolithiasis, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), agranulocytosis, aplastic anemia, skin rashes.

Interaction

Antiglaucoma drugs (beta-blockers, pilocarpine, dipivefrin, carbachol) enhance the effect of dorzolamide.
When used simultaneously with acetazolamide, the risk of developing systemic side effects increases.

Increased toxicity is possible when taking large doses of acetylsalicylic acid.

Overdose

Symptoms: disturbances in water and electrolyte metabolism, acidosis, disorders of the central nervous system (CNS).

Treatment: symptomatic. Monitoring electrolyte levels (especially K+) and blood pH levels.

Manufacturer

K.O.Rompharm Company S.R.L., Romania